Sophie Paget-Bailly
Affiliations: | Paris-Sud XI University, Orsay, Essonne, France |
Area:
Cancer, Larynx, Pharynx, Oral cavity, Upper aerodigestive tract, Occupational exposuresGoogle:
"Sophie Paget-Bailly"Parents
Sign in to add mentor| Danièle Luce | grad student | 2012 | Paris-Sud University | |
| (Facteurs de risque professionnels des cancers des voies aéro-digestives supérieures : Synthèse des données épidémiologiques et analyse d’une étude cas-témoins, l’étude Icare) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mamguem Kamga A, Di Martino C, Anota A, et al. (2020) Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial. Trials. 21: 527 |
| Vardanega J, Henriques J, Pourcelot C, et al. (2019) [Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction]. Bulletin Du Cancer |
| Pivot X, Romieu G, Debled M, et al. (2019) 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet (London, England) |
| Curtit E, Henriques J, Paget-Bailly S, et al. (2019) Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients. Journal of Clinical Oncology. 37: 1529-1529 |
| Pivot X, Romieu G, Debled M, et al. (2019) Abstract GS2-07: PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer Cancer Research. 79 |
| Ferrara R, Imbimbo M, Paget-Bailly S, et al. (2019) Single or combined immune checkpoint inhibitors compared to first‐line chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer Cochrane Database of Systematic Reviews |
| André T, Vernerey D, Mineur L, et al. (2018) 3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760355 |
| Pourcelot C, Orillard E, Nallet G, et al. (2018) Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. Breast Cancer Research and Treatment |
| Klajer E, Paget-Bailly S, Meynard G, et al. (2018) Impact of BRCA status on outcomes and survival in high-risk early breast cancers. Annals of Oncology. 29 |
| Turpin A, Paget-Bailly S, Ploquin A, et al. (2017) Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. Clinical Colorectal Cancer |